Clinical trials: NSCLC (non-small Cell Lung Cancer)
Lung Cancer
Stereotactic Radiosurgery in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. PURPOSE: This phase I trial is studying the side effects and best dose of stereotactic radiosurgery in treating…
- Trial name
- NCT00852644
- Testing
- computed tomography, fludeoxyglucose F 18, hypofractionated radiation therapy
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Boston Medical Center
Non Small Cell Lung Cancer
PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)
In this feasibility study, a zirconium-89 (89Zr)-avelumab positron emission tomography (PET) scan will be performed in 37 patients prior to treatment with avelumab to: 1.
- Trial name
- PINNACLE (NCT03514719)
- Testing
- 89Zr-avelumab PET, Avelumab
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- Radboud University Medical Center
NSCLC
Drug Concentration Monitoring of Pembrolizumab in Non-Small Cell Lung Cancer Patients
This observational study explores associations between drug trough-levels and clinical outcomes in Non Small Cell Lung Cancer (NSCLC) patients treated with immunotherapy (pembrolizumab) either alone or combined with chemotherapy.
- Trial name
- Oncomabs (NCT04557007)
- Testing
- Pembrolizumab
- Where
- Norway
- Volunteers
- 80 people
- Sponsor
- Oslo University Hospital
Carcinoma, Non Small Cell Lung
Healthy Directions After Lung Surgery Pilot
The objective of this proposal is to test the feasibility and acceptability of a lifestyle risk reduction intervention for patients with lung cancer receiving surgical treatment.
- Trial name
- NCT02135211
- Testing
- Lifestyle counseling
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- Dana-Farber Cancer Institute
Lung Cancer
Nivolumab in Combination With Chemotherapy, or Nivolumab in Combination With Ipilimumab, in Advanced EGFR-Mutant or ALK-Rearranged NSCLC
This research study is studying a drug intervention as a possible treatment for lung cancer. The drugs involved in this study are: Nivolumab Carboplatin Pemetrexed Ipilimumab
- Trial name
- NCT03256136
- Testing
- Carboplatin, Nivolumab, pemetrexed
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Massachusetts General Hospital
Advanced Cancer
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor shown in preclinical models to inhibit a closely related spectrum of RTKs including MET, AXL, MER, and members of the VEGFR, PDGFR, DDR2, TRK and Eph families.
- Trial name
- NCT02219711
- Testing
- MGCD516
- Where
- 43 sites in United States, South Korea
- Volunteers
- 193 people
- Sponsor
- Mirati Therapeutics Inc.
Lung Cancer
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
The study is to evaluate the effect of amrubicin (AMR) compared to docetaxel (DOC) in the treatment of non-small cell lung cancer (NSCLC).
- Trial name
- NCT01207011
- Testing
- Amrubicin hydrocloride, Docetaxel
- Where
- Japan
- Volunteers
- 202 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Non Small Cell Lung Cancer
Veristrat as Predictor of Benefit of First Line Non Small Cell Lung Cancer (NSCLC) Patients From Standard Chemotherapy
VeriStrat® is a pretreatment blood-based test correlated with clinical outcome after EGFR-TKI therapy in non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT02055144
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Non-small Cell Lung Cancer, Bone Metastasis
Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer
This study will give comparison of the bone pain remission and the adverse reaction of Zoledronic acid combine with High dose fractionation radiotherapy(30Gy/10f) and Zoledronic acid combine with low dose fractionation…
- Trial name
- NCT02480634
- Testing
- Zoledronic acid, Radiotherapy
- Volunteers
- 280 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Lung Cancer
Lung Cancer STARS Trial - STARS Revised Clinical Trial Protocol: Stereotactic Ablative Radiotherapy (SABR) in Stage I Non-small Cell Lung Cancer Patients Who Can Undergo Lobectomy
The goal of this clinical research study is to evaluate the outcome of a standard radiation treatment called stereotactic radiotherapy (SRT) for NSCLC.
- Trial name
- NCT02357992
- Testing
- Stereotactic Body Radiotherapy (SABR)
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2)…
- Trial name
- NCT04380636
- Testing
- Pembrolizumab, Olaparib, Etoposide
- Where
- 205 sites in United States, Argentina and 24 more
- Volunteers
- 870 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer, Adult Soft Tissue Sarcoma
Vaccine Therapy in Treating Patients With Metastatic Cancer
RATIONALE: Vaccines made from a peptide may make the body build an immune response and kill tumor cells. PURPOSE: Randomized phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic…
- Conditions
- Lung Cancer, Adult Soft Tissue Sarcoma, Colorectal Cancer, Bone Cancer
- Trial name
- NCT00020267
- Testing
- interleukin-2, MAGE-12 peptide vaccine, Montanide ISA-51
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Non Small Cell Lung Cancer
Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC Patients
Evaluate the Efficacy and Safety of Sintilimab Combined with Metformin Hydrochloride in Patients with Advanced Non-small Cell Lung Cancer Refractory to First-Line Platinum-Containing Chemotherapy
- Trial name
- SMART (NCT03874000)
- Testing
- Sintilimab, Metformin Hydrochloride
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), HER2
Observational, Prospective, Multi-centric Study Exploring HER2 Mutations Incidence and Therapeutic Management in aNSCLC
The HEROS study is an Italian observational multicenter prospective study aimed to investigate the current diagnostic and therapeutical approach towards HER2 mutated NSCLC in clinical practice.
- Trial name
- HEROS (NCT07356544)
- Where
- 22 sites in Italy
- Volunteers
- 50 people
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
Lung Cancer
Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)
The epidermal growth factor receptor (EGFR) is a key regulator of growth, differentiation, and survival of epithelial cancers. In a small subset of tumors, the presence of activating mutations within the ATP binding site confers…
- Trial name
- NCT00452244
- Testing
- simvastatin, gefitinib only
- Where
- South Korea
- Volunteers
- 110 people
- Sponsor
- National Cancer Center, Korea
Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer
A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
This study will look at the safety of the combination of three drugs (CDX-1401, Poly-ICL, and Pembrolizumab) and its effect on decreasing tumors. Pembrolizumab is an experimental cancer drug.
- Conditions
- Non Small Cell Lung Cancer, Advanced Triple Negative Breast Cancer, Small Cell Lung Cancer, Urothelial Cancer
- Trial name
- NCT02661100
- Testing
- Pembrolizumab, CDX-1401, Poly-ICLC
- Sponsor
- Case Comprehensive Cancer Center
Non Small Cell Lung Cancer, Urothelial Carcinoma
Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors
In this phase I first-in-humans-study a vaccine consisting of arginase-1 (ARG1) peptides and the adjuvant Montanide ISA-51 will be tested in ten patients with metastatic solid tumors.
- Conditions
- Non Small Cell Lung Cancer, Urothelial Carcinoma, Malignant Melanoma, Ovarian Cancer
- Trial name
- NCT03689192
- Testing
- ARG1-18,19,20
- Where
- Denmark
- Volunteers
- 13 people
- Sponsor
- Herlev Hospital
Non-small Cell Lung Cancer
dMR During First Line Treatment of Non Squamous Lung Cancer: Time Course and Prognostic and Predictive Impact.
To date, there are no methods to reliably select which patients with non-squamous non-small cell lung cancer (NSCLC) that benefit most from treatment with bevacizumab.
- Trial name
- BevMar (NCT02195336)
- Testing
- dMRT, Bevacizumab, paclitaxel and carboplatin
- Where
- Sweden
- Volunteers
- 20 people
- Sponsor
- Karl Kölbeck
NSCLC
Cabazitaxel in Relapsed and Metastatic NSCLC
The investigators propose to study the single agent activity of Cabazitaxel in a Phase II trial of subjects with relapsed or refractory non-small cell lung cancer pretreated with docetaxel, given the fact of its significant…
- Trial name
- NCT01852578
- Testing
- Cabazitaxel
- Where
- 5 sites in Greece
- Volunteers
- 46 people
- Sponsor
- Hellenic Oncology Research Group
Ewings Sarcoma, Non Small Cell Lung Cancer
Trial of Bi-shRNA-furin and GMCSF Augmented Autologous Tumor Cell Vaccine for Advanced Cancer
Autologous Vigil™ vaccine expresses rhGMCSF and bi-shRNAfurin from the Vigil™ plasmid. The GMCSF protein is a potent stimulator of the immune system, recruiting immune effectors to the site of intradermal injection and promoting…
- Conditions
- Ewings Sarcoma, Non Small Cell Lung Cancer, Liver Cancer
- Trial name
- NCT01061840
- Testing
- Vigil™
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Gradalis, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.